Home > News > Recent cases

Actavis -and- Eli Lilly [2017] UKSC 4812 July 2017Daniel Alexander QC, Richard Meade QC and Isabel Jamal appeared for the Claimant/Respondent, Actavis, in this landmark case in which the Supreme Court changed the way in which UK courts consider patent infringement by ‘equivalents’. The Supreme Court, allowing the appeal and finding that Actavis’s product both directly and indirectly infringed, substantially re-cast the English […]
Astex Therapeutics Ltd -v- Astrazeneca Ab [2017] EWHC 1442 (Ch)21 June 2017James Mellor QC and James Whyte appeared for the Defendant, AstraZeneca, in a case concerning payments under a collaboration agreement between AstraZeneca and the Claimant, Astex. The terms of the agreement provided that Astex were entitled to milestone payments in certain circumstances, and to royalties from sales of any products containing a “collaboration compound”. Astex […]
Federation International De L’automobile v Gator Sports Ltd16 June 2017Jonathan Hill successfully represented the Claimant (FIA), the sporting body in charge of motor sport, in a claim in the Chancery Division for trade mark infringement and passing off in relation to articles of clothing sold by the Defendant companies after expiry of an official merchandise license relating to the World Rally Championship (WRC). Shortly […]
Unwired Planet International Ltd v Huawei Technologies Co Ltd [2017] EWHC 1304 (Pat)8 June 2017Adrian Speck QC, Isabel Jamal and Thomas Jones appeared for the claimant, Unwired Planet, and Andrew Lykiardopoulos QC appeared for the defendant, Huawei, in this hearing which considered remedies, in particular the appropriate form of a “FRAND injunction”, following the Court’s earlier ruling ([2017] EWHC 711 (Pat)) on the terms of a FRAND licence. Among […]
Synthon v Teva [2017] EWCA Civ 14822 May 2017Andrew Lykiardopoulos QC represented the Appellant, Synthon, in its appeal concerning Teva’s patent for glatiramer acetate (marketed as “Copaxone”). The Patent related to a method of making glatiramer acetate with limited levels bromine and free metal impurities. Synthon had challenged the validity of the patent on grounds of lack of novelty, obviousness and insufficiency. At […]